Oncology News | pharmaphorum

News

ESMO: Roche’s Alecensa claims a first in ALK-positive NSCLC

Roche’s Alecensa has become the first drug in the ALK inhibitor class to significantly improve disease-free survival across all disease stages in a phase 3 trial involving

News

ESMO: Opdivo chases Keytruda in perioperative lung cancer

Just days after MSD claimed an FDA approval for Keytruda as a pre- and post-surgery option for early non-small cell lung cancer (NSCLC), Bristol-Myers Squibb has staked a

News

EU clears path for Pfizer’s takeover of Seagen

Pfizer’s $43 billion acquisition of antibody-drug conjugate specialist Seagen has been given the go-ahead by the authorities in the EU, clearing a key remaining obstacle t

News

MSD sinks $4bn upfront into ADC pact with Daiichi Sankyo

Daiichi Sankyo’s antibody-drug conjugate (ADC) franchise has generated another massive licensing deal, this time from MSD, which is paying $4 billion upfront for rights to

News

Lilly makes another ADC play, buying Mablink

Eli Lilly has agreed a deal to acquire French antibody-drug conjugate (ADC) specialist Mablink, continuing a series of transactions that build its position in what has bec

News

Seagen wins future royalties in Enhertu patent dispute

Daiichi Sankyo has been ordered to pay an 8% royalty rate on sales of its breast cancer therapy Enhertu by a Texas court, on top of an earlier award of $41.8 million in da

ESMO: Roche’s Alecensa claims a first in ALK-positive NSCLC

ESMO: Opdivo chases Keytruda in perioperative lung cancer

EU clears path for Pfizer’s takeover of Seagen

MSD sinks $4bn upfront into ADC pact with Daiichi Sankyo

Lilly makes another ADC play, buying Mablink

Seagen wins future royalties in Enhertu patent dispute

Syneron raises $150m for macrocylics, and other financings

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks